Skip Navigation

Cardiovascular Research 2006 72(1):1-2; doi:10.1016/j.cardiores.2006.07.024
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fandrey, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fandrey, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

A cordial affair – erythropoietin and cardioprotection

Joachim Fandrey*

Institut für Physiologie, Universität Duisburg-Essen, Hufelandstrasse 55, D-45122 Essen, Germany

* Tel./fax: +49 201 723 4600/4648. Email address: joachim.fandrey@uni-due.de

Received 20 July 2006; accepted 25 July 2006

The first 10% of the full text of this article appears below.

See article by Burger et al. [8] (pages 51–59) in this issue.

Hypoxia and erythropoietin (EPO) were a couple from the very beginning. Hypoxia induces the production of EPO, which became the paradigm for oxygen-regulated gene expression [1]. Dissecting EPO gene regulation has lead to the discovery of the transcription factor complex hypoxia inducible factor-1 (HIF-1), the widespread "master regulator of O2 homeostasis" in the tissue, and the identification of cellular oxygen sensors in control of HIF-1 (reviewed by [2]). EPO as a erythropoietic hormone is mainly synthesized . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
K. M. Kirschner, P. Hagen, C. S. Hussels, M. Ballmaier, H. Scholz, and C. Dame
The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells
FASEB J, August 1, 2008; 22(8): 2690 - 2701.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J.-C. Fauchere, C. Dame, R. Vonthein, B. Koller, S. Arri, M. Wolf, and H. U. Bucher
An Approach to Using Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants
Pediatrics, August 1, 2008; 122(2): 375 - 382.
[Abstract] [Full Text] [PDF]